PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

IMG-20170807-WA0029
DJI 0020
20170731 192225
IMG-20170802-WA0013
IMG-20170806-WA0009
DJI 0018
  • Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • Human medicines European public assessment report (EPAR): Voxzogo, vosoritide, Date of authorisation: 26/08/2021, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • Human medicines European public assessment report (EPAR): Effentora, fentanyl, Date of authorisation: 04/04/2008, Revision: 32, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Date of authorisation: 20/09/2017, Revision: 35, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • Human medicines European public assessment report (EPAR): Ozawade, pitolisant, Date of authorisation: 01/09/2021, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-18
  • GDUFA Paid Facilities List
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-18 By FDA
  • ANDA Assessment Program | GDUFA III Performance Goals and Program Enhancements
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-18 By FDA
  • Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-17 By FDA
  • Search for Pharmaceutical Quality Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-17 By FDA
  • Generic Drugs - Specific Labeling Resources
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-17 By FDA
  • Apitoria Pharma Private Limited Unit 1 - 618091 - 11/13/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-17 By FDA
  • Aurobindo Pharmaceutical Limited - 618091 - 01/12/2022
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-17 By FDA
  • Patent Certifications and Suitability Petitions
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-17 By FDA
Older posts
Theme: Scaffold by Danny Cooper.